ARES vs CNS

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 11, 2026

ARES

36.3
AI Score
VS
ARES Wins

CNS

34.6
AI Score

Investment Advisor Scores

ARES

36score
Recommendation
EXTENDED

CNS

35score
Recommendation
AVOID NEW MONEY

AI Analyst Insights

Detailed Metrics Comparison

Metric ARES CNS Winner
Forward P/E 18.6567 18.1159 CNS
PEG Ratio 0.9926 1.3225 ARES
Revenue Growth -18.7% 11.1% CNS
Earnings Growth -81.9% 0.0% CNS
Tradestie Score 36.3/100 34.6/100 ARES
Profit Margin 8.7% 28.2% CNS
Beta 1.00 1.00 Tie
AI Recommendation EXTENDED AVOID NEW MONEY ARES

Relative Price Performance (Last 90 Days)

ARES 1M: +19.3% · 3M: -7.7% CNS 1M: +5.6% · 3M: -15.1%

Current Technical Phase

ARES

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 65

RSI (14): 65.5 · Price: $137.89

CNS

Distribution
Trim / tighten stop

Price near a flattening SMA50 (slope -5.6%) with fading momentum, RSI 50

RSI (14): 49.8 · Price: $72.72

Fundamentals Snapshot

Metric ARES CNS
Market Cap — —
Forward P/E 19.8 19.6
Trailing P/E 114.3 22.7
Revenue (TTM) — —
Revenue Growth -0.2% 0.1%
Gross Margin 1.0% 0.5%
Operating Margin 0.1% 0.3%
EPS 1.22 3.25
Dividend Yield 0.04% 0.04%

Frequently Asked Questions

Based on our detailed analysis, ARES is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.